Trial Profile
PROACTYVE Pilot: Pilot Study of Patient's Adherence to TYKERB/TYVERB + Capecitabine in Metastatic Breast Cancer - Observation of Patient Adherence and Evaluation of Predictive Factors for Patient Adherence After Providing Educational Programme.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms PROACTYVE
- Sponsors GlaxoSmithKline; GSK
- 03 Nov 2011 New trial record